Peptron Receives Patent Approval for Tirzepatide Long-Acting Formulation
Applicable to Long-Acting GLP-1 Formulations Including Semaglutide and Tirzepatide
Strengthening Pipeline IP for Obesity and Metabolic Disorders Based on SmartDepot™
Peptron, a company specializing in developing sustained-release peptide-based pharmaceuticals, announced on October 1 that it has received approval for a domestic patent registration for its long-acting formulations that can be applied to GLP-1 class drugs such as semaglutide and tirzepatide.
This patent relates to sustained-release formulation technology that enables the long-term release of GLP-1 class drugs. It represents a key intellectual property right for applying Peptron's long-acting drug delivery platform, SmartDepot™, to the field of obesity and metabolic disorders.
Peptron is currently developing a semaglutide-based long-acting treatment (PT403), which is administered once a month, as well as a tirzepatide-based long-acting formulation (PT404). The company is pursuing both in-house development and global business development activities.
According to Peptron, this registration decision strengthens its domestic rights foundation for long-acting formulations of major GLP-1 class drugs and secures intellectual property that can be leveraged in future global partnering and commercialization initiatives.
Peptron is also seeking to secure patent rights in major overseas countries by filing corresponding applications internationally. Depending on the examination results of each country's patent office, registration eligibility will be determined for each region.
Hot Picks Today
"From 20s to 60s, Everyone Rushed In"...The 'Top License' Also Obtained by Actors Yoo Yeon-seok and Sung Hoon Revealed
- [Exclusive] "Extra Pension Without Ever Setting Foot in Korea"... Baffling Loophole in Foreigners' Childbirth Credit
- "Such chaos for the first time in 140 years"... Even illnesses surge, Tokyo stunned by 'unbelievable' event
- "Even Mushy When Pressed With a Fork": Family of Three Suffers Abdominal Pain and Diarrhea After Eating Chicken at Yeosu Island Expo, Another Food Safety Controversy Erupts
- "Nothing Left to Buy, Feeling Indifferent"... 'Rich Daughter' Vibe in Department Stores with 'Hyunbaek Core'
A Peptron representative stated, "The approval of this patent registration is significant as it further strengthens the intellectual property foundation for GLP-1 long-acting formulations utilizing SmartDepot™," adding, "We will continue to expand our business development opportunities with global pharmaceutical companies alongside the development of PT403 and PT404 so that these efforts lead to the successful commercialization of long-acting formulations."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
